YMAB Historical Balance Sheet

YMAB Stock

USD 5.00 0.08 1.63%

Trend analysis of Y mAbs Therapeutics balance sheet accounts such as Total Assets of 148.1 M, Other Current Liab of 8.5 M, Total Current Liabilities of 18.7 M or Total Stockholder Equity of 124.9 M provides information on Y MAbs' total assets, liabilities, and equity, which is the actual value of Y mAbs Therapeutics to its prevalent stockholders. By breaking down trends over time using Y MAbs balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Y mAbs Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Y mAbs Therapeutics is a good buy for the upcoming year.

Y MAbs Inventory

5.21 Million

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Y mAbs Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

About YMAB Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Y mAbs Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Y MAbs Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Y MAbs and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which YMAB currently owns. An asset can also be divided into two categories, current and non-current.

Y MAbs Balance Sheet Chart

At present, Y MAbs' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Stockholder Equity is expected to grow to about 124.9 M, whereas Other Current Liabilities is forecasted to decline to about 8.5 M.

Total Assets Other Current Liab Total Current Liabilities Total Stockholder Equity Other Liab

Add Fundamental

Total Assets

Total assets refers to the total amount of Y MAbs assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Y mAbs Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Y MAbs balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Y mAbs Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most accounts from Y MAbs' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Y mAbs Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Y mAbs Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	12.4M	13.2M	16.4M	8.5M
Total Assets	141.5M	127.9M	119.9M	148.1M

Other Current Liab Total Assets

Y MAbs balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Other Assets	Deferred Long Term Liab	Net Invested Capital	Net Working Capital	Property Plant And Equipment Net
Total Assets		0.67	0.81	1.0	0.43	0.99	-0.95	-0.68	0.86	0.97	0.97	0.88	0.55	0.77	0.64	0.82	0.88	0.83	0.81	1.0	0.88	0.44	-0.23	0.85	0.78	0.7
Other Current Liab	0.67		0.93	0.6	0.65	0.66	-0.45	-0.96	0.72	0.48	0.48	0.89	0.92	0.84	0.74	0.96	0.76	0.96	0.93	0.61	0.89	0.28	-0.41	0.31	0.17	0.42
Total Current Liabilities	0.81	0.93		0.75	0.7	0.78	-0.64	-0.93	0.92	0.67	0.67	0.93	0.9	0.81	0.78	0.96	0.91	0.97	1.0	0.77	0.93	0.46	-0.32	0.49	0.38	0.66
Total Stockholder Equity	1.0	0.6	0.75		0.36	0.99	-0.96	-0.61	0.83	0.99	0.99	0.84	0.47	0.74	0.58	0.77	0.84	0.77	0.75	1.0	0.84	0.43	-0.21	0.87	0.82	0.67
Other Liab	0.43	0.65	0.7	0.36		0.4	-0.27	-0.71	0.56	0.31	0.31	0.69	0.72	0.59	0.84	0.69	0.78	0.69	0.74	0.38	0.69	0.14	-0.29	0.09	-0.01	0.67
Net Tangible Assets	0.99	0.66	0.78	0.99	0.4		-0.94	-0.66	0.81	0.97	0.97	0.88	0.52	0.8	0.6	0.81	0.85	0.81	0.77	0.99	0.88	0.41	-0.27	0.85	0.78	0.65
Net Debt	-0.95	-0.45	-0.64	-0.96	-0.27	-0.94		0.43	-0.77	-0.98	-0.98	-0.73	-0.3	-0.62	-0.47	-0.67	-0.77	-0.65	-0.63	-0.96	-0.72	-0.45	-0.03	-0.92	-0.89	-0.71
Retained Earnings	-0.68	-0.96	-0.93	-0.61	-0.71	-0.66	0.43		-0.75	-0.51	-0.51	-0.89	-0.94	-0.81	-0.81	-0.92	-0.81	-0.95	-0.94	-0.63	-0.9	-0.23	0.55	-0.29	-0.16	-0.46
Accounts Payable	0.86	0.72	0.92	0.83	0.56	0.81	-0.77	-0.75		0.8	0.8	0.83	0.72	0.68	0.63	0.83	0.89	0.84	0.91	0.85	0.84	0.52	-0.2	0.63	0.56	0.74
Cash	0.97	0.48	0.67	0.99	0.31	0.97	-0.98	-0.51	0.8		1.0	0.76	0.37	0.66	0.51	0.68	0.8	0.68	0.67	0.99	0.76	0.44	-0.16	0.9	0.87	0.69
Cash And Short Term Investments	0.97	0.48	0.67	0.99	0.31	0.97	-0.98	-0.51	0.8	1.0		0.76	0.37	0.66	0.51	0.68	0.8	0.68	0.67	0.99	0.76	0.44	-0.16	0.9	0.87	0.69
Common Stock Total Equity	0.88	0.89	0.93	0.84	0.69	0.88	-0.73	-0.89	0.83	0.76	0.76		0.8	0.92	0.8	0.97	0.9	0.97	0.94	0.84	1.0	0.27	-0.35	0.56	0.44	0.65
Common Stock Shares Outstanding	0.55	0.92	0.9	0.47	0.72	0.52	-0.3	-0.94	0.72	0.37	0.37	0.8		0.67	0.81	0.86	0.74	0.88	0.91	0.49	0.81	0.35	-0.44	0.2	0.07	0.52
Short Term Investments	0.77	0.84	0.81	0.74	0.59	0.8	-0.62	-0.81	0.68	0.66	0.66	0.92	0.67		0.6	0.86	0.73	0.86	0.8	0.73	0.93	0.14	-0.51	0.4	0.28	0.39
Non Current Liabilities Total	0.64	0.74	0.78	0.58	0.84	0.6	-0.47	-0.81	0.63	0.51	0.51	0.8	0.81	0.6		0.81	0.86	0.83	0.83	0.59	0.8	0.25	-0.22	0.34	0.25	0.73
Capital Surpluse	0.82	0.96	0.96	0.77	0.69	0.81	-0.67	-0.92	0.83	0.68	0.68	0.97	0.86	0.86	0.81		0.89	0.99	0.97	0.78	0.96	0.36	-0.28	0.53	0.4	0.63
Other Current Assets	0.88	0.76	0.91	0.84	0.78	0.85	-0.77	-0.81	0.89	0.8	0.8	0.9	0.74	0.73	0.86	0.89		0.9	0.93	0.86	0.9	0.46	-0.24	0.65	0.56	0.84
Other Stockholder Equity	0.83	0.96	0.97	0.77	0.69	0.81	-0.65	-0.95	0.84	0.68	0.68	0.97	0.88	0.86	0.83	0.99	0.9		0.98	0.78	0.97	0.33	-0.35	0.51	0.38	0.6
Total Liab	0.81	0.93	1.0	0.75	0.74	0.77	-0.63	-0.94	0.91	0.67	0.67	0.94	0.91	0.8	0.83	0.97	0.93	0.98		0.77	0.94	0.44	-0.32	0.49	0.37	0.69
Total Current Assets	1.0	0.61	0.77	1.0	0.38	0.99	-0.96	-0.63	0.85	0.99	0.99	0.84	0.49	0.73	0.59	0.78	0.86	0.78	0.77		0.84	0.45	-0.21	0.87	0.82	0.69
Common Stock	0.88	0.89	0.93	0.84	0.69	0.88	-0.72	-0.9	0.84	0.76	0.76	1.0	0.81	0.93	0.8	0.96	0.9	0.97	0.94	0.84		0.27	-0.4	0.55	0.44	0.64
Other Assets	0.44	0.28	0.46	0.43	0.14	0.41	-0.45	-0.23	0.52	0.44	0.44	0.27	0.35	0.14	0.25	0.36	0.46	0.33	0.44	0.45	0.27		0.1	0.54	0.52	0.57
Deferred Long Term Liab	-0.23	-0.41	-0.32	-0.21	-0.29	-0.27	-0.03	0.55	-0.2	-0.16	-0.16	-0.35	-0.44	-0.51	-0.22	-0.28	-0.24	-0.35	-0.32	-0.21	-0.4	0.1		0.07	0.14	0.11
Net Invested Capital	0.85	0.31	0.49	0.87	0.09	0.85	-0.92	-0.29	0.63	0.9	0.9	0.56	0.2	0.4	0.34	0.53	0.65	0.51	0.49	0.87	0.55	0.54	0.07		0.99	0.67
Net Working Capital	0.78	0.17	0.38	0.82	-0.01	0.78	-0.89	-0.16	0.56	0.87	0.87	0.44	0.07	0.28	0.25	0.4	0.56	0.38	0.37	0.82	0.44	0.52	0.14	0.99		0.63
Property Plant And Equipment Net	0.7	0.42	0.66	0.67	0.67	0.65	-0.71	-0.46	0.74	0.69	0.69	0.65	0.52	0.39	0.73	0.63	0.84	0.6	0.69	0.69	0.64	0.57	0.11	0.67	0.63

Click cells to compare fundamentals

Y MAbs Account Relationship Matchups

Y MAbs balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	132.0M	212.8M	141.5M	127.9M	119.9M	148.1M
Other Current Liab	6.2M	10.8M	12.4M	13.2M	16.4M	8.5M
Total Current Liabilities	19.5M	27.9M	28.3M	20.1M	23.7M	18.7M
Total Stockholder Equity	105.8M	180.1M	109.2M	101.0M	92.0M	124.9M
Other Liab	2.2M	4.7M	3.0M	3.1M	3.5M	3.0M
Net Tangible Assets	198.9M	105.8M	178.4M	106.2M	122.2M	129.5M
Net Debt	(110.7M)	(177.9M)	(104.0M)	(77.2M)	(66.4M)	(69.7M)
Retained Earnings	(285.2M)	(340.5M)	(436.0M)	(457.5M)	(487.1M)	(462.8M)
Accounts Payable	9.4M	13.6M	14.2M	6.1M	6.7M	8.8M
Cash	114.6M	181.6M	105.8M	78.6M	67.2M	123.5M
Non Current Assets Total	9.7M	10.5M	11.0M	16.8M	21.4M	22.5M
Non Currrent Assets Other	3.3M	3.2M	5.7M	12.5M	18.3M	19.2M
Cash And Short Term Investments	114.6M	181.6M	105.8M	78.6M	67.2M	123.5M
Common Stock Shares Outstanding	40.1M	43.2M	43.7M	43.6M	44.3M	42.2M
Liabilities And Stockholders Equity	132.0M	212.8M	141.5M	127.9M	119.9M	148.1M
Non Current Liabilities Total	6.7M	4.8M	4.0M	6.8M	4.2M	4.5M
Capital Surpluse	225.4M	364.7M	391.6M	519.2M	597.1M	304.2M
Other Current Assets	7.7M	7.5M	5.5M	5.0M	4.4M	4.8M
Other Stockholder Equity	391.6M	519.2M	543.9M	558.0M	576.9M	408.0M
Total Liab	26.2M	32.7M	32.2M	26.9M	27.9M	23.2M
Total Current Assets	122.4M	202.3M	130.4M	111.1M	98.5M	138.9M
Accumulated Other Comprehensive Income	(526K)	1.4M	1.3M	449K	2.3M	2.4M
Other Assets	7.9M	206.9M	5.7M	1.0	1.15	1.09
Net Invested Capital	105.8M	180.1M	109.2M	101.0M	92.0M	101.0M
Net Working Capital	102.8M	174.4M	102.2M	91.0M	74.8M	96.9M
Property Plant And Equipment Net	6.4M	5.7M	2.3M	1.6M	859K	816.1K
Property Plant And Equipment Gross	6.4M	5.7M	2.3M	1.6M	859K	816.1K
Non Current Liabilities Other	6.7M	4.8M	802K	864K	812K	771.4K
Property Plant Equipment	4.0M	1.8M	5.7M	2.3M	2.7M	3.1M
Short Long Term Debt Total	4.0M	3.6M	1.8M	1.4M	820K	779K
Capital Lease Obligations	4.0M	3.6M	1.8M	1.4M	820K	779K
Short Term Debt	3.9M	3.6M	1.7M	902K	630K	598.5K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether Y mAbs Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Y MAbs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Y Mabs Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Y Mabs Therapeutics Stock:

How To Invest In YMAB

Details

Is YMAB Stock a good investment?

Details

What is Y MAbs' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Y MAbs. If investors know YMAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Y MAbs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.67)

Revenue Per Share

1.978

Quarterly Revenue Growth

0.134

Return On Assets

(0.13)

Return On Equity

(0.31)

The market value of Y mAbs Therapeutics is measured differently than its book value, which is the value of YMAB that is recorded on the company's balance sheet. Investors also form their own opinion of Y MAbs' value that differs from its market value or its book value, called intrinsic value, which is Y MAbs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Y MAbs' market value can be influenced by many factors that don't directly affect Y MAbs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Y MAbs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Y MAbs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Y MAbs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

YMAB Historical Balance Sheet

Y MAbs Inventory

5.21 Million

About YMAB Balance Sheet Analysis

Y MAbs Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Y MAbs balance sheet Correlations

Y MAbs Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Y MAbs balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Total Current Assets	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash
Common Stock	+ 1.0	Common Stock Total Equity

Cash And Short Term Investments	- 0.98	Net Debt
Cash	- 0.98	Net Debt
Total Current Assets	- 0.96	Net Debt
Net Debt	- 0.96	Total Stockholder Equity
Retained Earnings	- 0.96	Other Current Liab
Other Stockholder Equity	- 0.95	Retained Earnings